ClinicalTrials.gg
RecruitingNCT07931326Updated Nov 12, 2026

Cerebral Desaturation Burden After Interscalene or Suprascapular-Axillary Block for Shoulder Arthroscopy

An interventional study of Ultrasound-Guided Interscalene Nerve Block and ltrasound-Guided Combined Suprascapular and Axillary Nerve Blocks in Cerebral Oxygenation During Shoulder Arthroscopy, sponsored by Ataturk University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Ataturk University · Not applicable, Interventional, and Treatment

Updated Nov 12, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Shoulder arthroscopy is often performed with the patient in an upright beach-chair position. Changes in position and anesthesia may affect blood pressure and oxygen delivery to the brain. This study compares two ultrasound-guided nerve block approaches performed before general anesthesia: interscalene block and combined suprascapular and axillary nerve blocks. Participants will be randomly assigned to one of these approaches. Both groups will receive the same general anesthetic and 20 mL of 0.25% bupivacaine for the assigned block approach. Cerebral oxygen saturation will be monitored continuously using sensors placed on the forehead. The main outcome is the total cerebral desaturation burden, measured as the area below 80% of each participant's baseline cerebral oxygen saturation during monitoring. Other outcomes include the occurrence and duration of desaturation, minimum cerebral oxygen saturation, blood pressure and heart rate events, vasopressor use, and immediate recovery and a Mini-Mental State Examination to assess cognitive functions.

02

Conditions studied

  • Cerebral Oxygenation During Shoulder Arthroscopy

Keywords

  • Interscalene Block
  • Suprascapular Nerve Block
  • Axillary Nerve Block
  • Beach-Chair Position
  • Cerebral Desaturation
  • Near-Infrared Spectroscopy
  • Shoulder Arthroscopy
03

In context

Lead sponsor

Ataturk University is the lead sponsor of 460 studies on the registry; 126 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years
  • I or II
  • Scheduled for elective shoulder arthroscopy under general anesthesia in the beach-chair position
  • Provides written

Exclusion criteria

Exclusion Criteria:

  • Allergy to local anesthetics
  • Previous cervical spine surgery
  • History of cerebrovascular disease or carotid artery surgery
  • Serious cardiac disease, including advanced heart failure or significant valvular disease
  • Neurological disease, including epilepsy, multiple sclerosis, or Parkinson's disease
  • Dementia or cognitive impairment
  • Coagulopathy or to peripheral nerve block due to anticoagulant use
  • Pregnancy
  • greater than 35 kg/m²
  • Technical or anatomical obstacle to performing the planned nerve block
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Interscalene Block (ISB)

    Participants will receive a preoperative ultrasound-guided interscalene nerve block using 20 mL of 0.25% bupivacaine.

    Procedure: Ultrasound-Guided Interscalene Nerve Block

  • Experimental
    Combined Suprascapular and Axillary Nerve Blocks (SSAX)

    Participants will receive preoperative ultrasound-guided suprascapular and axillary nerve blocks. A total of 20 mL of 0.25% bupivacaine will be divided between the two blocks.

    Procedure: ltrasound-Guided Combined Suprascapular and Axillary Nerve Blocks

Interventions

  • ProcedureUltrasound-Guided Interscalene Nerve Block

    A preoperative ultrasound-guided interscalene block will be performed with the patient supine and the head turned to the opposite side. A total of 20 mL of 0.25% bupivacaine will be injected around the brachial plexus roots.

  • Procedureltrasound-Guided Combined Suprascapular and Axillary Nerve Blocks

    Preoperative ultrasound-guided suprascapular and axillary nerve blocks will be performed. A total of 20 mL of 0.25% bupivacaine will be divided between the two block sites.

06

What researchers measure

Primary outcomes

  1. Total Cerebral Desaturation Burden (AUC)

    The area under the curve below the desaturation threshold, defined as 80% of baseline regional cerebral oxygen saturation (rSO₂). AUC will be calculated separately for each hemisphere; the mean of the two hemispheres will be used for the primary comparison. Only desaturation episodes lasting at least 15 seconds will be included. The unit is %·min.

    Time frame: From baseline measurement before the nerve block until 10 minutes after return to the supine position.

Secondary outcomes

  1. Incidence and Number of Cerebral Desaturation Events

    Proportion of participants with, and number of, cerebral desaturation events, defined as a decrease in rSO₂ of at least 20% from baseline lasting at least 15 seconds.

    Time frame: From baseline measurement before the nerve block until 10 minutes after return to the supine position.

  2. Total Time Below the Cerebral Desaturation Threshold

    Total time during which rSO₂ remains below 80% of baseline.

    Time frame: From baseline measurement before the nerve block until 10 minutes after return to the supine position.

  3. Minimum Right and Left Cerebral rSO₂

    Minimum rSO₂ values recorded from the right and left frontal hemispheres; values will be assessed separately.

    Time frame: From baseline measurement before the nerve block until 10 minutes after return to the supine position.

  4. Ipsilateral and Contralateral Cerebral Desaturation Burden

    AUC below the desaturation threshold in the cerebral hemisphere ipsilateral and contralateral to the operated shoulder.

    Time frame: From baseline measurement before the nerve block until 10 minutes after return to the supine position.

  5. Incidence of Intraoperative Hypotension and Bradycardia

    Proportion of participants with hypotension, defined as a decrease in baseline systolic blood pressure of more than 20% or MAP below 65 mmHg, and bradycardia, defined as heart rate below 50 beats/min.

    Time frame: During the intraoperative period.

  6. Total Intraoperative Ephedrine and Norepinephrine Dose

    Total ephedrine dose in mg and total norepinephrine dose in µg administered intraoperatively.

    Time frame: During the intraoperative period.

  7. Post-Anesthesia Care Unit Length of Stay

    Time elapsed, in minutes, from postoperative admission to the post-anesthesia care unit to discharge to the surgical ward. Patients are discharged when the Modified Aldrete Score reaches 9 or higher.

    Time frame: Perioperative period (immediate postoperative recovery, from post-anesthesia care unit admission to discharge).

  8. Modified Aldrete Score at Post-Anesthesia Care Unit Discharge

    The Modified Aldrete Score is recorded at discharge from the post-anesthesia care unit to the surgical ward. The scale assesses activity, respiration, circulation, consciousness, and oxygen saturation. Each component is scored from 0 to 2, yielding a total score ranging from 0 to 10. Higher scores indicate better physiological recovery from anesthesia. Patients are discharged when the total score reaches 9 or higher.

    Time frame: Perioperative period (at discharge from the post-anesthesia care unit).

  9. Assessment of cognitive functions at the 24th postoperative hour

    A Mini-Mental State Examination was performed at the 24th postoperative hour to assess cognitive functions.

    Time frame: At the 24th postoperative hour

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS, Vaughn J, Nisman M. Cerebral oxygen desaturation events assessed by near-infrared spectroscopy during shoulder arthroscopy in the beach chair and lateral decubitus positions. Anesth Analg. 2010 Aug;111(2):496-505. doi: 10.1213/ANE.0b013e3181e33bd9. Epub 2010 May 27. PubMed 20508134 ↗
  • Thanaboriboon C, Vanichvithya P, Jinaworn P. What Is the Risk of Intraoperative Cerebral Oxygen Desaturation in Patients Undergoing Shoulder Surgery in the Beach Chair Position? Clin Orthop Relat Res. 2021 Dec 1;479(12):2677-2687. doi: 10.1097/CORR.0000000000001864. PubMed 34128914 ↗
  • Harsanji Drenjancevic I, Drenjancevic D, Davidovic-Cvetko E, Drenjancevic I, Gulam D, Kvolik S. DOES THE ANESTHESIA TECHNIQUE AFFECT ARTERIAL PRESSURE AND REGIONAL CEREBRAL OXYGEN SATURATION DURING SHOULDER ARTHROSCOPY IN THE BEACH CHAIR POSITION? Acta Clin Croat. 2018 Sep;57(3):473-479. doi: 10.20471/acc.2018.57.03.10. PubMed 31168180 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2026 (actual). Primary completion is estimated for Dec 2026, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 12, 2026
StartActual
Nov 10, 2026
Primary completionEst.
Dec 29, 2026
CompletionEst.
Dec 29, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07931326
Lead sponsor
Ataturk University
Responsible party
Muhammed E Aydin (Principal Investigator, Ataturk University) — Principal investigator
First posted
Nov 12, 2026
Start date
Nov 10, 2026
Primary completion
Dec 29, 2026 (estimated)
Completion
Dec 29, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Muhammed Enes Aydin, Associate Professor
Contact
enesmd@msn.com
+905543318289
Emir Sahan, assistant doctor
Contact
Emirsahan94@gmail.com
+905332773733

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion